SCHEMBL5564885

SCHEMBL5564885

C=C(C(=O)c1ccc(S(=O)(=O)NCc2cccnc2)cc1)c1cc(-c2cccs2)c(OC)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NAMPT P43490 2/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560851 0.83 L3MBTL1 (0.39) ALDH1A1MEN1KMT2AMAPT
SCHEMBL5566988 0.83 KMT2A (0.51) SMN1; SMN2LMNAHPGDHTTALDH1A1
SCHEMBL5564750 0.83 PKM (0.46) PKMSMN1; SMN2LMNAHPGDHTT
SCHEMBL5564888 0.82 TNFRSF1A (0.54) PKMSMN1; SMN2LMNAHPGDHTT
SCHEMBL5564890 0.82 TNFRSF1A (0.54) PKMSMN1; SMN2LMNAHPGDHTT
SCHEMBL5566178 0.82 TNFRSF1A (0.39) SMN1; SMN2LMNAHPGDHTTALDH1A1
SCHEMBL5561089 0.81 TNFRSF1A (0.39) SMN1; SMN2LMNAHPGDHTTALDH1A1
SCHEMBL5565370 0.80 MEN1 (0.51) PKMLMNAALDH1A1MEN1KMT2A
SCHEMBL5564220 0.80 CYP19A1 (0.51) LMNAALDH1A1KMT2ANAMPT
SCHEMBL5560946 0.80 RXFP1 (0.49) SMN1; SMN2HPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 PKM 2155/4885SMN1; SMN2 1575/4885LMNA 2762/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 PKM 2155/4885SMN1; SMN2 1575/4885LMNA 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.